ATE475430T1 - Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls - Google Patents

Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls

Info

Publication number
ATE475430T1
ATE475430T1 AT04782353T AT04782353T ATE475430T1 AT E475430 T1 ATE475430 T1 AT E475430T1 AT 04782353 T AT04782353 T AT 04782353T AT 04782353 T AT04782353 T AT 04782353T AT E475430 T1 ATE475430 T1 AT E475430T1
Authority
AT
Austria
Prior art keywords
boris
brother
regulator
molecule
cancer vaccine
Prior art date
Application number
AT04782353T
Other languages
English (en)
Inventor
Michael G Agadjanyan
Anahit Ghochikyan
Original Assignee
Univax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univax Llc filed Critical Univax Llc
Application granted granted Critical
Publication of ATE475430T1 publication Critical patent/ATE475430T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Inert Electrodes (AREA)
AT04782353T 2003-08-25 2004-08-25 Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls ATE475430T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49751103P 2003-08-25 2003-08-25
PCT/US2004/027856 WO2005021029A2 (en) 2003-08-25 2004-08-25 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)

Publications (1)

Publication Number Publication Date
ATE475430T1 true ATE475430T1 (de) 2010-08-15

Family

ID=34272574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04782353T ATE475430T1 (de) 2003-08-25 2004-08-25 Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls

Country Status (12)

Country Link
US (2) US7579452B2 (de)
EP (1) EP1667711B1 (de)
JP (1) JP2007504154A (de)
CN (1) CN1871025B (de)
AT (1) ATE475430T1 (de)
AU (1) AU2004268001B2 (de)
CA (1) CA2537161C (de)
DE (1) DE602004028381D1 (de)
DK (1) DK1667711T3 (de)
IL (1) IL173943A (de)
RU (2) RU2385163C2 (de)
WO (1) WO2005021029A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2325866T3 (es) 2004-09-21 2009-09-22 Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Procedimiento de deteccion de cancer en base a una reaccion inmune a boris.
US20090081245A1 (en) * 2007-09-07 2009-03-26 Reznik Boris N Assays for development of boris mutants suitable for vaccine development and small molecule inhibitors of wild-type boris
EP2376089B1 (de) 2008-11-17 2018-03-14 The Regents of the University of Michigan Krebsvakzine-zusammensetzungen und anwendungsverfahren dafür
CN105764921B (zh) * 2013-09-17 2020-06-30 台湾浩鼎生技股份有限公司 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途
CA2962558C (en) * 2014-09-24 2023-12-12 Sapporo Medical University A brother of the regulator of imprinted sites (boris)-derived tumor antigen peptide
EP3297652A4 (de) 2015-05-19 2019-06-05 La Jolla Institute for Allergy and Immunology Humane apob100-epitope, verfahren und verwendungen zur modulation von entzündungsreaktionen und behandlung von unerwünschten kardiovaskulären ereignissen, krankheiten und atherosklerose
WO2017041027A1 (en) 2015-09-04 2017-03-09 Obi Pharma, Inc. Glycan arrays and method of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017172990A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
MY200886A (en) 2016-04-22 2024-01-22 Obi Pharma Inc Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
AU2017302038B2 (en) 2016-07-27 2024-03-21 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
TWI767959B (zh) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
CN111479585A (zh) * 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向boris的癌症疫苗和其用途
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
UY24367A1 (es) * 1995-11-23 2000-10-31 Boehringer Ingelheim Int Vacunas contra tumores y procedimiento para su produccion
CN1326974A (zh) * 2000-06-07 2001-12-19 上海博德基因开发有限公司 一种新的多肽——人转录阻抑蛋白ccctc－结合因子(ctcf)10.23和编码这种多肽的多核苷酸
WO2002083879A2 (en) * 2001-04-02 2002-10-24 Alimentary Health Limited Immunotherapy based on dendritic cells
AU2003225589A1 (en) * 2002-02-22 2003-09-09 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Brother of the regulator of imprinted sites (boris)

Also Published As

Publication number Publication date
US20060286115A1 (en) 2006-12-21
RU2006109359A (ru) 2007-10-10
RU2556128C2 (ru) 2015-07-10
CA2537161C (en) 2014-07-29
AU2004268001B2 (en) 2010-04-22
US8114405B2 (en) 2012-02-14
EP1667711A2 (de) 2006-06-14
CA2537161A1 (en) 2005-03-10
RU2010110441A (ru) 2011-09-27
IL173943A (en) 2011-04-28
IL173943A0 (en) 2006-07-05
DK1667711T3 (da) 2010-11-22
CN1871025A (zh) 2006-11-29
WO2005021029A2 (en) 2005-03-10
WO2005021029A3 (en) 2005-05-26
AU2004268001A1 (en) 2005-03-10
US20100166790A1 (en) 2010-07-01
JP2007504154A (ja) 2007-03-01
EP1667711B1 (de) 2010-07-28
DE602004028381D1 (en) 2010-09-09
RU2385163C2 (ru) 2010-03-27
US7579452B2 (en) 2009-08-25
CN1871025B (zh) 2013-06-05

Similar Documents

Publication Publication Date Title
IL173943A0 (en) Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
DE60232870D1 (de) Neue polynukleotide und polypeptide des erythropoietingens
DE69928658T2 (de) Basb029 polynucleotide und polypeptide aus neisseria meningitis
DE60213221D1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
ATE334231T1 (de) Neue polynukleotide und polypeptide des ifn alpha-17-gens
DE69941433D1 (de) Von protease typ ii spaltbares peptid
ATE311476T1 (de) Polymorphismen im gen für den humanen organischen anionentransporter c (oatp-c)
BR0317161A (pt) Moléculas de ligação nogo a e uso farmacêutico das mesmas
CY1108280T1 (el) Basb205 πολυπεπτιδια και πολυνουκλεοτιδια που τα κωδικοποιουν
DK1112366T3 (da) Polynucleotider og polypeptider BASB033 fra Neisseria Meningitidis samt deres anvendelser
WO2003093305A3 (en) Teneurin c-terminal associated peptides (tcap) and uses thereof
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE60336015D1 (de) Menschliche Gene in Verbindung mit Krebs, davon kodierte Produkte und Anwendungen davon
DE60320835D1 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
ATE443715T1 (de) Polypeptide aus haemophilus influenza
WO2003074675A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002072765A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002077190A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002077193A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002068648A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these humans ras-like proteins, and uses thereof
ATE515511T1 (de) Nicht-typisierbare haemophilus influenzae basb201 polypeptide und polynukleotide und deren verwendungen
WO2002079494A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002074976A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002079407A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002079386A3 (en) Isolated human ras-like proteins, nucleic and acid molecules encoding these human ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1667711

Country of ref document: EP